期刊文献+

盐酸氨溴索干粉吸入剂理化性质及其初步稳定性考察 被引量:2

Study of Physicochemical Property and Stability of Ambroxol Hydrochloride Dry Powder Inhalations
原文传递
导出
摘要 目的:研究盐酸氨溴索干粉吸入剂的理化性质并考察其稳定性。方法:采用喷雾干燥法制备盐酸氨溴索干粉吸入剂;考察其吸湿性及临界相对湿度;观察其粒径分布、粉末形态;差示扫描量热(DSC)法分析吸入剂及其原料药和各辅料的特征峰;检测其排空率和沉积率;对制剂进行加速试验和长期试验以考察其稳定性。结果:所得干粉吸入剂的临界相对湿度约为64%,平均空气动力学径小于5μm,形态为粒径均匀的球形;DSC提示各样品特征峰未发生明显变化,即在喷雾干燥过程主药与辅料之间未发生相互作用;3批干粉吸入剂排空率均>90%,沉积率均>30%;稳定性试验中各指标在观察期内无明显变化。结论:所制盐酸氨溴索干粉吸入剂适合肺部吸入给药,且具有较好的稳定性。 OBJECTIVE: To study physicochemical property and stability of Ambroxol hydrochloride dry powder inhalations (AHDI). METHODS: AHDI were prepared by spray-drying method. The humidity and critical relative moisture of inhalations were investigated. The particle size and powder morphology were also observed. The characteristic peak of inhalations, raw material and excipients were analyzed by DSC. The emptying rate and deposition rate of it were determined. The stability of it was determined by accelerated test and long-term test. RESULTS: The resultant powder inhalation exhibited the following properties: 64% critical relative humidity, d~, was 〈5 μm; DSC showed that there wasn't interaction between main component and excipients; emptying rate was 〉90%, and deposition rate was 〉30% for 3 patches; the accelerated test and the long-term test indicated that AHDI was stable. CONCLUSION: AHDI are stable and suitable for pulmonary delivery system.
出处 《中国药房》 CAS CSCD 北大核心 2011年第29期2735-2737,共3页 China Pharmacy
基金 黑龙江省自然科学基金项目(D201031) 黑龙江省教育厅科学研究资助项目(11551178)
关键词 盐酸氨溴索 干粉吸入剂 理化性质 稳定性 Ambroxol hydrochloride Dry powder inhalation Physicochemical property Stability
  • 相关文献

参考文献8

  • 1Hohyu NK, Jeong-Yeon Y, Sang BH, et al. Determinati- on of ambroxol in human plasma using LC-MS/MS[J]. J PharmaceutBiomed, 2003, 32(2): 209.
  • 2Grainger CI, Alcock R, Gard TG, et al. Administration of an insulin powder to the lungs of cynomolgus monkeys using a Penn Century insuffiator[J]. Int J Pharm, 2004, 269(2) : 523.
  • 3Davis SS. Delivery of peptide and non-peptide drugs th- rough the respiratory tract[J]. Pharm Science Technol To- day, 1999, 2(11):450.
  • 4任亚超,王蕾,孟康康,唐星.盐酸氨溴索干粉吸入剂的制备工艺[J].沈阳药科大学学报,2008,25(7):519-523. 被引量:5
  • 5Maa YF, Nguyen PA, Andya JD, et al. Effect of spray drying and subsequent processing conditions on residual moisture content and physical/biochemical stability of pro- tein inhalation powders[J]. Pharm Res, 1998, I5(5) :768.
  • 6Shekkunoy BY, Feeley JC, Chow AH, et al. Aerosolisa- tion behaviour of micronised and supercritically-pro- cessed powders[J]. JAerosol Sci, 2003, 34 (5) : 553.
  • 7Atkins PJ. Dry powder inhalers: an overview[J]. Respira- tory Care,2005, 50(10):1 304.
  • 8Larhrb H, Martin GP, Marriott C, et al. The inluence of carrier and drug morphology on drug delivery from dry powder formultions[J]. Int J Pharm, 2003, 257 (1-2) : 283.

二级参考文献17

  • 1赵应征,鲁翠涛,梅兴国.常用多指标综合评价法在优选实验中的应用[J].医学研究生学报,2004,17(7):624-626. 被引量:35
  • 2宋永辉,王艳红.盐酸氨溴索口服溶液改善COPD患者咳痰困难的疗效[J].实用心脑肺血管病杂志,2004,12(6):335-337. 被引量:6
  • 3HOHYU N K, JEONG-YEON Y, SANG B H, et al. Determination of ambroxol in human plasma using LCMS/MS [ J ]. J Pharmaceut Biomed, 2003, 32 ( 2 ) ."209 - 216.
  • 4GIBBS B F, SCHMUTZLER W, VOLLRATHL I B, et aI. Ambroxol inhibits the release of histamine, leukotrienes and cytokinesfrom human leukocytes and mast cells[J]. Inftamm Res, 1999, 48(2) :86 - 93.
  • 5YANG B, YAO D F, OHUCHI M, et aI. Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels [ J ]. Eur Respir J, 2002, 19(5) :952 - 958.
  • 6British Pharmacopoeia Commission Office. British Pharmacopoeia: Volume Ⅳ[ M ]. British: British Pharmacopoeia Commission Office, 2005; Appendix VQ A211 - A212.
  • 7BOSQUILLON C, PReAT V, VANBEVER R. Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats [ J ]. J Control Release, 2004, 96(2) :233 - 244.
  • 8ZENG X M, MARTIN G P, MARRIOTT C, et al. The influence of carrier morphology on drug delivery by dry powder inhalers[J]. Int J Pha Rm, 2000, (1) : 93 - 106.
  • 9OKAMOTO H, AOKI M, DANJO K. A novaI apparatus for rat in vivo evaluation of dry powder formulations for pulmonary administration [J]. J Pharm Sci (US), 2000, 89(8): 1028- 1035.
  • 10SHEKKUNOY B Y, FEELEY J C, CHOW A H, et al. Aerosolisation behaviour of micronised and supercriticallly-processed powders [ J ]. J Aerosol Sci, 2003, 34:553 - 568.

共引文献4

同被引文献3

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部